Delayed trial readouts
Studies whose primary completion date moved on ClinicalTrials.gov in the last 180 days, newest first. The primary completion date is the sponsor's own estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout. Our daily registry check records each move the day it sees it. Upcoming dates are on the readout calendar.
Summary
521 date moves in Phase 3 and 2/3 studies: 323 later and 198 earlier. The median move later is 183 days.
Date moves
| Seen | Drug | Study | Phase | Old date | New date | Move |
|---|---|---|---|---|---|---|
| 2026-11-20 | aldesleukin | NCT01704716High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) | Phase 3 | 2021-09-30 | 2025-01-30 | +1218 days |
| 2026-11-20 | Capecitabine, Gemcitabine, Eribulin mesylate | NCT06143553Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer | Phase 3 | 2025-12 | 2027-12-31 | +760 days |
| 2026-11-20 | Semaglutide (Ozempic) | NCT06387199Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide | Phase 2/3 | 2027-01 | 2027-12 | +334 days |
| 2026-11-20 | Letrozole | NCT04111978MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | Phase 3 | 2027-07-01 | 2028-02-01 | +215 days |
| 2026-11-20 | Rifaximin SSD | NCT05071716Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | Phase 3 | 2025-09 | 2025-12-23 | +113 days |
| 2026-11-20 | Zoledronic acid | NCT03295981Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone | Phase 3 | 2027-01 | 2027-04 | +90 days |
| 2026-11-20 | Oxycodone (Xtampza ER) | NCT03823534Post-Op Pain Control for Prophylactic Intramedullary Nailing. | Phase 3 | 2026-12-31 | 2027-03-31 | +90 days |
| 2026-11-20 | Goserelin | NCT07777263ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV) | Phase 3 | 2035-10 | 2035-12 | +61 days |
| 2026-11-20 | Semaglutide (Wegovy) | NCT07845994SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years | Phase 3 | 2031-02 | 2031-03 | +28 days |
| 2026-11-19 | Anakinra | NCT05805930Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children | Phase 3 | 2025-06-01 | 2027-10-01 | +852 days |
| 2026-11-19 | Povetacicept | NCT07204275Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) | Phase 2/3 | 2028-12-29 | 2029-06-27 | +180 days |
| 2026-11-19 | AND017 | NCT07494409A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia | Phase 3 | 2026-10-30 | 2027-02-20 | +113 days |
| 2026-11-19 | AND017 | NCT07487727A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) | Phase 3 | 2026-12-01 | 2027-03-01 | +90 days |
| 2026-11-19 | Dexamethasone, Cevostamab, Elotuzumab, Pomalidomide, Daratumumab, Carfilzomib | NCT07555938Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | Phase 3 | 2028-10-31 | 2028-11-30 | +30 days |
| 2026-11-19 | Depemokimab, Mepolizumab | NCT05263934Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | 2026-09-29 | 2026-10-06 | +7 days |
| 2026-11-18 | tenofovir alafenamide (Vemlidy), lamivudine (Epivir-HBV), Tenofovir disoproxil fumarate (Viread), Doravirine, Bictegravir | NCT07075146DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity | Phase 3 | 2026-06-05 | 2027-12-05 | +548 days |
| 2026-11-18 | Methotrexate, etanercept | NCT03728478STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS | Phase 3 | 2025-02-28 | 2025-10-31 | +245 days |
| 2026-11-18 | faricimab | NCT06790784Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR | Phase 3 | 2031-08 | 2032-02 | +184 days |
| 2026-11-18 | viloxazine | NCT02736656Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | Phase 3 | 2026-09 | 2026-12 | +91 days |
| 2026-11-18 | Temozolomide | NCT07935889Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 Trial | Phase 3 | 2035-11-02 | 2035-11-30 | +28 days |
| 2026-11-17 | zasocitinib | NCT07250802A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis | Phase 3 | 2033-01-24 | 2034-07-03 | +525 days |
| 2026-11-17 | Iparomlimab and tuvonralimab | NCT07613567QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer | Phase 3 | 2032-08-31 | 2032-12-31 | +122 days |
| 2026-11-17 | HRG2010 | NCT06596876A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations | Phase 3 | 2025-10-09 | 2026-01-29 | +112 days |
| 2026-11-17 | Dostarlimab | NCT07740720A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer | Phase 3 | 2029-12-12 | 2030-03-13 | +91 days |
| 2026-11-14 | Rosuvastatin, Laroprovstat | NCT06834932A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | Phase 2/3 | 2025-07-03 | 2027-02-22 | +599 days |
| 2026-11-14 | Omega-3-acid ethyl esters (Lovaza) | NCT02178410VITAL Rhythm Study | Phase 3 | 2026-10 | 2027-10 | +365 days |
| 2026-11-14 | upadacitinib | NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | Phase 3 | 2028-03 | 2028-08 | +153 days |
| 2026-11-14 | Trastuzumab Emtansine, Inavolisib | NCT05894239A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | 2026-12-31 | 2027-05-03 | +123 days |
| 2026-11-14 | ADSTEM | NCT07377838Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis | Phase 3 | 2029-06 | 2029-09 | +92 days |
| 2026-11-14 | Suzetrigine | NCT07654296Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery | Phase 3 | 2026-12-31 | 2027-03-31 | +90 days |
| 2026-11-13 | Methylprednisolone | NCT05139849VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial | Phase 3 | 2027-01-31 | 2029-01-31 | +731 days |
| 2026-11-13 | Docetaxel, OSE2101 | NCT06472245Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | Phase 3 | 2027-12-15 | 2028-05-01 | +138 days |
| 2026-11-13 | Vadadustat | NCT06520826Vafseo Outcomes In-Center Experience | Phase 3 | 2026-06-30 | 2026-09-10 | +72 days |
| 2026-11-13 | Everolimus | NCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | Phase 3 | 2026-12-30 | 2027-02-26 | +58 days |
| 2026-11-13 | Gemcitabine | NCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | Phase 2/3 | 2029-01-01 | 2029-01-31 | +30 days |
| 2026-11-13 | Odronextamab, Rituximab | NCT06091254A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | 2028-02-07 | 2028-02-29 | +22 days |
| 2026-11-13 | Ruxolitinib (Opzelura) | NCT06959225Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | Phase 3 | 2026-10-09 | 2026-10-29 | +20 days |
| 2026-11-11 | Methotrexate | NCT02205762LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis | Phase 2/3 | 2026-07 | 2031-11 | +1949 days |
| 2026-11-11 | Fianlimab, Cemiplimab, Pembrolizumab | NCT05608291A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | Phase 3 | 2026-07-27 | 2027-01-15 | +172 days |
| 2026-11-11 | zenagamtide, Semaglutide (Ozempic) | NCT07400107AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Phase 3 | 2028-12-12 | 2028-12-19 | +7 days |
| 2026-11-10 | IncobotulinumtoxinA (Xeomin) | NCT00909883Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles) | Phase 3 | 2011-09 | 2013-11-12 | +803 days |
| 2026-11-08 | Bosentan | NCT02377271ENDOTHELION Study Group: Effect of Bosentan in NAION Patients | Phase 3 | 2023-12 | 2027-02 | +1158 days |
| 2026-11-08 | Tarlatamab, Durvalumab | NCT06211036Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab | Phase 3 | 2027-07-05 | 2030-04-02 | +1002 days |
| 2026-11-08 | Olanzapine (Zyprexa) | NCT06200181Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial | Phase 3 | 2026-11-01 | 2027-11-01 | +365 days |
| 2026-11-08 | Pertuzumab | NCT02320435A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial | Phase 3 | 2026-12-31 | 2027-03-28 | +87 days |
| 2026-11-08 | Bevacizumab | NCT07851025Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer | Phase 3 | 2030-06-18 | 2030-06-28 | +10 days |
| 2026-11-07 | Famitinib, Camrelizumab | NCT05999149A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) | Phase 3 | 2025-08-30 | 2026-05-30 | +273 days |
| 2026-11-07 | Dostarlimab | NCT05201547Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line | Phase 3 | 2026-04 | 2026-10-01 | +183 days |
| 2026-11-07 | Fampridine | NCT06136728Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis | Phase 3 | 2026-12 | 2027-05 | +151 days |
| 2026-11-07 | Ziltivekimab | NCT06263244Specifying the Anti-inflammatory Effects of Ziltivekimab | Phase 3 | 2026-09-04 | 2026-10-30 | +56 days |
| 2026-11-06 | baricitinib | NCT05056558Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19 | Phase 3 | 2022-04 | 2025-07-30 | +1216 days |
| 2026-11-06 | Dexamethasone | NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | 2028-08-02 | 2028-11-30 | +120 days |
| 2026-11-06 | Aflibercept, Tabirafusp tedromer, Tarcocimab tedromer | NCT06556368A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Phase 3 | 2026-08 | 2026-09-02 | +32 days |
| 2026-11-06 | Furosemide (subcutaneous, SQ Innovation) | NCT07018297Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure | Phase 3 | 2028-08-01 | 2028-09-01 | +31 days |
| 2026-11-06 | maridebart cafraglutide, Semaglutide (Ozempic) | NCT07866066Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Phase 3 | 2028-09-04 | 2028-09-06 | +2 days |
| 2026-11-05 | Hydroxychloroquine, Dexamethasone, apremilast, tocilizumab, Sarilumab, Anakinra, baricitinib | NCT02735707Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Phase 3 | 2026-02 | 2028-06 | +851 days |
| 2026-11-05 | Sintilimab, Nab-paclitaxel | NCT05429463Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC(neoSCORE Ⅱ) | Phase 3 | 2025-11-11 | 2026-11-30 | +384 days |
| 2026-11-05 | Sotagliflozin (Inpefa) | NCT07211802CKM For Safe Use of SGLT2i in Type 1 Diabetes | Phase 3 | 2030-07-31 | 2031-07-31 | +365 days |
| 2026-11-05 | metformin | NCT06452498Preeclampsia Intervention Netherlands | Phase 3 | 2028-04 | 2029-03-19 | +352 days |
| 2026-11-05 | Rituximab, Nivolumab | NCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | Phase 3 | 2026-12-31 | 2027-06-30 | +181 days |
| 2026-11-05 | Monalizumab, Oleclumab, Durvalumab | NCT05221840A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | Phase 3 | 2026-09-30 | 2027-01-08 | +100 days |
| 2026-11-05 | Dapagliflozin | NCT07295223Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial) | Phase 3 | 2026-08 | 2026-10-30 | +90 days |
| 2026-11-05 | Albuterol sulfate (Proventil HFA), albuterol (Armstrong Albuterol HFA), fluticasone propionate | NCT06052267A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Phase 3 | 2026-10-31 | 2026-12-31 | +61 days |
| 2026-11-05 | Risdiplam (Evrysdi) | NCT05115110A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy | Phase 2/3 | 2026-10-28 | 2026-11-02 | +5 days |
| 2026-11-04 | metformin | NCT04177303Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment | Phase 3 | 2022-11-29 | 2024-12-31 | +763 days |
| 2026-11-04 | jaktinib | NCT05676242A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis | Phase 3 | 2024-12 | 2026-03-12 | +466 days |
| 2026-11-04 | dupilumab | NCT02612454Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | Phase 3 | 2026-10-07 | 2026-10-09 | +2 days |
| 2026-11-03 | Furmonertinib | NCT05607550Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) | Phase 3 | 2025-08-15 | 2026-10-06 | +417 days |
| 2026-11-03 | Hydroxychloroquine | NCT05287321The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia | Phase 3 | 2026-12-31 | 2027-12-31 | +365 days |
| 2026-11-01 | Rituximab | NCT03560011Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome | Phase 2/3 | 2021-01-07 | 2022-11-04 | +666 days |
| 2026-11-01 | Bemdaneprocel (MSK-DA01) | NCT06944522A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | Phase 3 | 2027-03 | 2028-10 | +580 days |
| 2026-11-01 | Bevacizumab | NCT07286266A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) | Phase 3 | 2029-12-17 | 2030-07-22 | +217 days |
| 2026-11-01 | Pumitamig | NCT06616532PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer | Phase 3 | 2027-01-25 | 2027-05 | +96 days |
| 2026-11-01 | N-acetylcysteine, metformin | NCT06836128The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients | Phase 3 | 2026-02-01 | 2026-03-30 | +57 days |
| 2026-11-01 | Bevacizumab | NCT07816666Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | Phase 3 | 2028-09-26 | 2028-09-29 | +3 days |
| 2026-11-01 | Goserelin, Methylprednisolone, Docetaxel | NCT04787744Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer | Phase 2/3 | 2026-09-30 | 2026-10-02 | +2 days |
| 2026-10-31 | Vigabatrin (Sabril) | NCT04987463Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants | Phase 2/3 | 2026-03 | 2028-12 | +1006 days |
| 2026-10-31 | Trastuzumab pamirtecan, Trastuzumab Emtansine | NCT06265428A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer | Phase 3 | 2026-02 | 2027-12 | +668 days |
| 2026-10-31 | metformin | NCT05468554Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer | Phase 3 | 2026-04-30 | 2028-01-31 | +641 days |
| 2026-10-31 | Sintilimab | NCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | Phase 2/3 | 2025-01 | 2026-08-28 | +604 days |
| 2026-10-31 | Mevrometostat | NCT06629779A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | Phase 3 | 2026-12-02 | 2027-09-30 | +302 days |
| 2026-10-31 | Dexamethasone, Rituximab, Methotrexate | NCT03150693Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | Phase 3 | 2027-03-01 | 2027-11-01 | +245 days |
| 2026-10-31 | Rifaximin (Xifaxan) | NCT07522255Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders | Phase 3 | 2027-10 | 2028-06 | +244 days |
| 2026-10-31 | Tricaprilin | NCT05809908Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study | Phase 3 | 2029-06 | 2030-01 | +214 days |
| 2026-10-31 | Docetaxel | NCT04784715Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | Phase 3 | 2026-11-11 | 2027-05-03 | +173 days |
| 2026-10-31 | Adebrelimab, Bevacizumab | NCT07691762A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma | Phase 3 | 2031-04 | 2031-09 | +153 days |
| 2026-10-31 | Rituximab, Venetoclax | NCT03984448Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | Phase 2/3 | 2028-04-01 | 2028-08-13 | +134 days |
| 2026-10-31 | Telikibart | NCT06516302A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps | Phase 3 | 2026-03 | 2026-06-12 | +103 days |
| 2026-10-31 | Mevrometostat, Docetaxel | NCT06551324A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | Phase 3 | 2026-12-28 | 2027-02-28 | +62 days |
| 2026-10-31 | Ammoxetine | NCT06827431The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression | Phase 3 | 2026-06-30 | 2026-07-14 | +14 days |
| 2026-10-29 | Trastuzumab Deruxtecan | NCT06174987A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) | Phase 3 | 2026-08-03 | 2028-02-17 | +563 days |
| 2026-10-29 | hepalatide | NCT07309380Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D | Phase 3 | 2027-06 | 2028-06 | +366 days |
| 2026-10-29 | Gabapentin | NCT04724252Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children | Phase 2/3 | 2026-12-31 | 2027-12-31 | +365 days |
| 2026-10-29 | Ferric derisomaltose | NCT05407987Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) | Phase 3 | 2026-12-30 | 2027-12-30 | +365 days |
| 2026-10-29 | Pembrolizumab | NCT04534205A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | Phase 2/3 | 2028-08 | 2029-04 | +243 days |
| 2026-10-29 | lebrikizumab | NCT06339008A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) | Phase 3 | 2026-09 | 2026-10-22 | +51 days |
| 2026-10-29 | Lenbelintide | NCT07784270A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight | Phase 3 | 2028-08-08 | 2028-08-09 | +1 day |
| 2026-10-28 | survodutide | NCT07855900SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Phase 3 | 2028-06-25 | 2029-11-06 | +499 days |
| 2026-10-28 | Ordastobart, Pembrolizumab | NCT06295731Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN) | Phase 2/3 | 2029-05 | 2029-12 | +214 days |
| 2026-10-27 | Staccato Alprazolam | NCT05077904A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures | Phase 3 | 2026-10-31 | 2027-03-29 | +149 days |
| 2026-10-27 | Cabotegravir/rilpivirine (Cabenuva) | NCT06507059Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals | Phase 3 | 2025-07-01 | 2025-08-06 | +36 days |
| 2026-10-27 | Dapagliflozin | NCT06783166Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure | Phase 2/3 | 2025-07-01 | 2025-07-04 | +3 days |
| 2026-10-26 | Everolimus | NCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | Phase 2/3 | 2025-01 | 2026-08-28 | +604 days |
| 2026-10-26 | Ipilimumab | NCT03793166Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | Phase 3 | 2028-01-25 | 2028-03-01 | +36 days |
| 2026-10-26 | Ravulizumab | NCT07596784Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | Phase 3 | 2027-08-17 | 2027-08-24 | +7 days |
| 2026-10-24 | Pembrolizumab | NCT03711032Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | Phase 3 | 2026-07-31 | 2028-07-31 | +731 days |
| 2026-10-24 | Rimegepant (Nurtec ODT) | NCT06616194A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine | Phase 3 | 2028-08-19 | 2030-02-26 | +556 days |
| 2026-10-24 | metformin | NCT04578652Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance | Phase 3 | 2026-09 | 2027-02 | +153 days |
| 2026-10-24 | Tolvaptan | NCT04782258A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) | Phase 3 | 2028-07-31 | 2028-12-28 | +150 days |
| 2026-10-24 | Exemestane, Letrozole, Anastrozole, Tamoxifen (Soltamox) | NCT04906395Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | Phase 3 | 2026-11-30 | 2027-01-30 | +61 days |
| 2026-10-23 | Gemcitabine | NCT07286266A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) | Phase 3 | 2029-12-17 | 2030-07-22 | +217 days |
| 2026-10-23 | Pertuzumab, Trastuzumab Deruxtecan | NCT04784715Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | Phase 3 | 2026-11-11 | 2027-05-03 | +173 days |
| 2026-10-23 | HB0017 | NCT06477237Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis | Phase 3 | 2024-08 | 2024-11-15 | +106 days |
| 2026-10-22 | Capecitabine, Eribulin mesylate, Sacituzumab Tirumotecan, Nab-paclitaxel | NCT06279364A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | Phase 3 | 2026-07 | 2027-04 | +274 days |
| 2026-10-22 | AZD0120, Lenalidomide | NCT07735637A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). | Phase 3 | 2028-10-11 | 2028-11-02 | +22 days |
| 2026-10-21 | N-acetylcysteine | NCT03900988Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia | Phase 3 | 2025-10-31 | 2027-10-31 | +730 days |
| 2026-10-21 | Fruquintinib, Axitinib | NCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | Phase 2/3 | 2025-01 | 2026-08-28 | +604 days |
| 2026-10-20 | Cetuximab, Pembrolizumab | NCT06589804Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | Phase 3 | 2029-11-30 | 2032-12-25 | +1121 days |
| 2026-10-20 | Gemcitabine, pemetrexed, Pembrolizumab | NCT04267848Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | 2027-01-31 | 2030-01-31 | +1096 days |
| 2026-10-20 | metformin | NCT06763328Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy | Phase 3 | 2029-06-16 | 2031-06-16 | +730 days |
| 2026-10-20 | Afrezza | NCT06535789Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes | Phase 2/3 | 2025-07 | 2026-09-05 | +431 days |
| 2026-10-20 | Dexamethasone, Etentamig, Lenalidomide, Daratumumab | NCT07095452A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | Phase 2/3 | 2040-09 | 2041-03 | +181 days |
| 2026-10-20 | tanruprubart | NCT07020819An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) | Phase 3 | 2026-12-31 | 2027-05-31 | +151 days |
| 2026-10-20 | tradipitant | NCT06836557Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis | Phase 3 | 2025-12 | 2026-03-30 | +119 days |
| 2026-10-20 | Pembrolizumab | NCT03244384Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer | Phase 3 | 2026-10-31 | 2027-01-01 | +62 days |
| 2026-10-20 | Nivolumab, Cabozantinib | NCT03793166Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | Phase 3 | 2028-01-25 | 2028-03-01 | +36 days |
| 2026-10-17 | upadacitinib | NCT06332534Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease | Phase 3 | 2027-06 | 2031-01 | +1310 days |
| 2026-10-17 | Dapagliflozin | NCT05944016Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients | Phase 3 | 2026-09 | 2027-09 | +365 days |
| 2026-10-17 | Eptinezumab (Vyepti) | NCT04965675A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | Phase 3 | 2026-09-05 | 2027-03-26 | +202 days |
| 2026-10-17 | dupilumab, upadacitinib | NCT06389136A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | Phase 3 | 2026-08 | 2026-11 | +92 days |
| 2026-10-17 | deucravacitinib | NCT04908202A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs | Phase 3 | 2024-09-05 | 2024-10-10 | +35 days |
| 2026-10-17 | nemolizumab | NCT07762833Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis | Phase 3 | 2027-09-28 | 2027-10-28 | +30 days |
| 2026-10-16 | Dapagliflozin, metformin | NCT05601336Dapagliflozin Versus Metformin and Their Combination in Polycystic Ovary Syndrome | Phase 3 | 2023-07-30 | 2026-05-01 | +1006 days |
| 2026-10-16 | BGM0504 | NCT06716203A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | Phase 3 | 2025-12-29 | 2026-11-14 | +320 days |
| 2026-10-16 | BGM0504, Semaglutide (Ozempic) | NCT06716216A Study of BGM0504 in Participants With Type 2 Diabetes | Phase 3 | 2026-03-20 | 2026-11-14 | +239 days |
| 2026-10-16 | Pembrolizumab | NCT07286266A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) | Phase 3 | 2029-12-17 | 2030-07-22 | +217 days |
| 2026-10-16 | BGM0504 | NCT06704581A Study of BGM0504 Injection in Participants With Obesity or Overweight | Phase 3 | 2025-11-27 | 2026-03-17 | +110 days |
| 2026-10-16 | pemetrexed, Datopotamab Deruxtecan, Osimertinib | NCT06417814A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | 2026-09-30 | 2027-01-11 | +103 days |
| 2026-10-15 | Docetaxel, Goserelin | NCT03678025Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | 2028-04-01 | 2033-04-01 | +1826 days |
| 2026-10-15 | Somatropin | NCT06103513Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children | Phase 3 | 2025-06-10 | 2028-01-05 | +939 days |
| 2026-10-15 | Apatinib, Camrelizumab | NCT05062837Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | Phase 2/3 | 2024-09-30 | 2026-12-30 | +821 days |
| 2026-10-15 | Gemcitabine | NCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | Phase 2/3 | 2026-12-01 | 2029-01-01 | +762 days |
| 2026-10-15 | Gemcitabine | NCT04574960Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) | Phase 3 | 2026-12 | 2027-12 | +365 days |
| 2026-10-15 | Trastuzumab Emtansine | NCT05296798A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | Phase 3 | 2027-10-31 | 2028-06-15 | +228 days |
| 2026-10-15 | Pumitamig, Atezolizumab | NCT06712355Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | Phase 3 | 2028-12 | 2029-04 | +121 days |
| 2026-10-15 | Capsaicin (Qutenza) | NCT06023706Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia. | Phase 3 | 2027-01-08 | 2027-05-08 | +120 days |
| 2026-10-15 | Aripiprazole (Abilify), Cariprazine (QLM1016) | NCT06799559Study on the Efficacy and Safety of QLM1016 in Schizophrenia | Phase 3 | 2026-07 | 2026-10-23 | +114 days |
| 2026-10-15 | Venetoclax | NCT03836261Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | Phase 3 | 2027-01-31 | 2027-04-30 | +89 days |
| 2026-10-15 | AR1001 | NCT05531526Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) | Phase 3 | 2026-05 | 2026-06-29 | +59 days |
| 2026-10-15 | Pelacarsen | NCT07625306Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL | Phase 3 | 2028-12-07 | 2029-01-22 | +46 days |
| 2026-10-15 | remibrutinib | NCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS | Phase 3 | 2031-10-24 | 2031-10-29 | +5 days |
| 2026-10-15 | remibrutinib | NCT06846281Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Phase 3 | 2029-07-24 | 2029-07-25 | +1 day |
| 2026-10-14 | Denosumab (Prolia) | NCT04547348The DENOCHARCOT Trial | Phase 3 | 2025-10-01 | 2030-08-01 | +1765 days |
| 2026-10-14 | Cemiplimab, Nivolumab, Pembrolizumab, Atezolizumab | NCT05317858Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | Phase 3 | 2027-06-01 | 2031-06-01 | +1461 days |
| 2026-10-14 | Letrozole | NCT05316935GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients | Phase 2/3 | 2026-03-30 | 2028-03-30 | +731 days |
| 2026-10-14 | Letrozole | NCT06379113GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients | Phase 2/3 | 2026-03-30 | 2028-03-30 | +731 days |
| 2026-10-14 | Aficamten | NCT04848506Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM | Phase 2/3 | 2028-03 | 2029-03 | +365 days |
| 2026-10-14 | Nivolumab | NCT06022861A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | 2025-06 | 2026-05-17 | +350 days |
| 2026-10-14 | BGM0504, Semaglutide (Ozempic) | NCT07064486A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia | Phase 3 | 2026-07-31 | 2027-04-30 | +273 days |
| 2026-10-14 | Docetaxel | NCT03178552A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | Phase 2/3 | 2026-10-31 | 2027-06-30 | +242 days |
| 2026-10-14 | Azetukalner | NCT06775379A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Phase 3 | 2026-08 | 2026-10 | +61 days |
| 2026-10-14 | onabotulinumtoxinA | NCT05878951Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms | Phase 2/3 | 2026-09-01 | 2026-10 | +30 days |
| 2026-10-14 | Docetaxel | NCT05132075Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | Phase 3 | 2026-08-25 | 2026-09-03 | +9 days |
| 2026-10-13 | Obinutuzumab | NCT03836261Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | Phase 3 | 2027-01-31 | 2027-04-30 | +89 days |
| 2026-10-12 | Acalabrutinib | NCT03836261Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | Phase 3 | 2027-01-31 | 2027-04-30 | +89 days |
| 2026-10-10 | Alixorexton | NCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia | Phase 2/3 | 2028-06 | 2030-06 | +730 days |
| 2026-10-10 | Sacubitril/valsartan | NCT06693674Effect of Sacubitril-Valsartan on Cardiac Structure and Function | Phase 3 | 2026-12 | 2028-08 | +609 days |
| 2026-10-10 | garetosmab | NCT07559513A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) | Phase 3 | 2028-12-10 | 2030-07-08 | +575 days |
| 2026-10-10 | Zimislecel | NCT04786262A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes | Phase 3 | 2027-06-30 | 2027-12-31 | +184 days |
| 2026-10-10 | metformin | NCT02275845Medico-GDM Trial - Metformine to Prevent Gestational Diabetes Mellitus | Phase 3 | 2016-09 | 2017-03-03 | +183 days |
| 2026-10-09 | Azetukalner | NCT05716100A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | Phase 3 | 2026-10 | 2028-01 | +457 days |
| 2026-10-07 | Vildagliptin | NCT02849899Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period | Phase 3 | 2024-07 | 2026-06-05 | +704 days |
| 2026-10-07 | Vonaprument | NCT06510816A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | Phase 3 | 2026-10-31 | 2027-07-31 | +273 days |
| 2026-10-07 | fluticasone propionate | NCT06664619A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | 2026-09-19 | 2026-11-02 | +44 days |
| 2026-10-07 | Elismetrep | NCT07816367A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | Phase 3 | 2027-09 | 2027-10 | +30 days |
| 2026-10-07 | tilrekimig, dupilumab | NCT07783425A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema | Phase 3 | 2028-08-29 | 2028-09-08 | +10 days |
| 2026-10-06 | Telisotuzumab Adizutecan, pemetrexed, Osimertinib | NCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | Phase 2/3 | 2031-12 | 2036-11 | +1797 days |
| 2026-10-06 | Abemaciclib | NCT04967521SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma | Phase 3 | 2025-12 | 2027-12 | +730 days |
| 2026-10-06 | Finerenone | NCT06058585The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect | Phase 3 | 2028-08-30 | 2029-12-31 | +488 days |
| 2026-10-06 | Haloperidol, Olanzapine (Zyprexa) | NCT04833023HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial | Phase 3 | 2024-12 | 2025-09-25 | +298 days |
| 2026-10-03 | Exemestane, Letrozole, Fulvestrant, Everolimus, Anastrozole | NCT07024173A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer | Phase 3 | 2026-12 | 2027-08 | +243 days |
| 2026-10-03 | Giredestrant, Docetaxel, Pertuzumab | NCT05296798A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | Phase 3 | 2027-12-31 | 2028-06-15 | +167 days |
| 2026-10-03 | Isatuximab | NCT07732712Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells | Phase 2/3 | 2028-08-01 | 2028-12-31 | +152 days |
| 2026-10-02 | Dapagliflozin | NCT06759077Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life | Phase 3 | 2024-12-28 | 2026-03-28 | +455 days |
| 2026-10-02 | Tretinoin | NCT06447480Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients | Phase 3 | 2026-09-01 | 2027-09-01 | +365 days |
| 2026-10-02 | Ipilimumab, Nivolumab | NCT07338981The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. | Phase 3 | 2030-12 | 2031-12 | +365 days |
| 2026-10-02 | elecoglipron | NCT07775404A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus | Phase 3 | 2027-06-04 | 2028-04-06 | +307 days |
| 2026-10-02 | etanercept | NCT06596772A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis | Phase 3 | 2025-10 | 2026-02-20 | +142 days |
| 2026-10-01 | Eptinezumab (Vyepti) | NCT06428838Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context | Phase 3 | 2025-12-30 | 2028-03 | +792 days |
| 2026-10-01 | pemetrexed, Tremelimumab, Durvalumab | NCT04585490Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | Phase 3 | 2026-08 | 2026-12 | +122 days |
| 2026-09-30 | Temozolomide | NCT05685004Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | Phase 2/3 | 2026-12 | 2030-11 | +1431 days |
| 2026-09-30 | Lenacapavir (Sunlenca), Bictegravir | NCT06532656Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 | Phase 2/3 | 2026-11 | 2030-07 | +1338 days |
| 2026-09-30 | Nivolumab | NCT03811015Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer | Phase 3 | 2027-01-01 | 2030-01-31 | +1126 days |
| 2026-09-30 | Bevacizumab, Osimertinib | NCT04181060Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | 2026-12-31 | 2029-06-30 | +912 days |
| 2026-09-30 | Exemestane, Letrozole, Anastrozole, Tamoxifen (Soltamox) | NCT04906395Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | Phase 3 | 2026-04-30 | 2026-11-30 | +214 days |
| 2026-09-30 | Nivolumab | NCT02595944Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | Phase 3 | 2026-12-31 | 2027-05-31 | +151 days |
| 2026-09-30 | Ipilimumab, Nivolumab | NCT03604991Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery | Phase 2/3 | 2026-12-31 | 2027-03-31 | +90 days |
| 2026-09-30 | Giredestrant, Docetaxel, Pertuzumab | NCT05296798A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | Phase 3 | 2027-10-31 | 2027-12-31 | +61 days |
| 2026-09-30 | Staccato Alprazolam | NCT05077904A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures | Phase 3 | 2026-09-30 | 2026-10-31 | +31 days |
| 2026-09-29 | Epirubicin, Docetaxel | NCT05901428TCb vs EC-T in High Risk ER+/HER2- Breast Cancer | Phase 3 | 2026-06 | 2029-06 | +1096 days |
| 2026-09-29 | PF-08634404, Nivolumab | NCT07392892Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | Phase 2/3 | 2031-07-22 | 2032-01-15 | +177 days |
| 2026-09-29 | Deupsilocin | NCT06564818"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Phase 3 | 2026-08 | 2026-09-04 | +34 days |
| 2026-09-29 | tulisokibart | NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) | Phase 3 | 2026-08-01 | 2026-08-12 | +11 days |
| 2026-09-26 | Capecitabine | NCT05610163Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response | Phase 2/3 | 2026-09-30 | 2030-07-01 | +1370 days |
| 2026-09-26 | Ranibizumab | NCT06305416A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema | Phase 3 | 2025-10 | 2026-03-10 | +160 days |
| 2026-09-26 | Deupsilocin | NCT06605105Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) | Phase 3 | 2028-03-15 | 2028-06-06 | +83 days |
| 2026-09-26 | Deupsilocin | NCT06793397A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Phase 3 | 2027-03-18 | 2027-06-07 | +81 days |
| 2026-09-26 | Adebrelimab, Bevacizumab, Sintilimab | NCT06618664A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) | Phase 3 | 2026-09 | 2026-10 | +30 days |
| 2026-09-26 | Nab-paclitaxel, Relacorilant (Lifyorli) | NCT05257408Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | Phase 3 | 2025-03-24 | 2025-03-31 | +7 days |
| 2026-09-26 | Ponsegromab | NCT06989437A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | Phase 2/3 | 2028-01-17 | 2028-01-23 | +6 days |
| 2026-09-25 | Envafolimab | NCT05752136Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma | Phase 3 | 2025-04 | 2026-11-01 | +579 days |
| 2026-09-25 | Anifrolumab | NCT06455449A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) | Phase 3 | 2027-05-14 | 2028-01-10 | +241 days |
| 2026-09-25 | sildenafil | NCT07462260Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT) | Phase 2/3 | 2026-04 | 2026-09-23 | +175 days |
| 2026-09-25 | Methotrexate | NCT07501507Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments | Phase 2/3 | 2027-10 | 2028-02 | +123 days |
| 2026-09-25 | jaktinib | NCT05861128Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS) | Phase 3 | 2025-12 | 2026-03-04 | +93 days |
| 2026-09-25 | Dexamethasone, Mezigdomide, Carfilzomib | NCT05552976A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | Phase 3 | 2026-07-18 | 2026-09-28 | +72 days |
| 2026-09-25 | Capecitabine, Trastuzumab pamirtecan, Nab-paclitaxel | NCT06018337A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Phase 3 | 2026-06 | 2026-08-12 | +72 days |
| 2026-09-25 | Finerenone | NCT05457283A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria | Phase 3 | 2028-08-01 | 2028-08-07 | +6 days |
| 2026-09-24 | Capecitabine, Docetaxel, Disitamab Vedotin | NCT04400695A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 | Phase 3 | 2024-06-30 | 2027-12-31 | +1279 days |
| 2026-09-24 | Litifilimab | NCT05352919A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE) | Phase 3 | 2030-03-29 | 2032-05-03 | +766 days |
| 2026-09-24 | Palbociclib, Cetuximab | NCT04966481Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor | Phase 3 | 2028-02-28 | 2029-02-28 | +366 days |
| 2026-09-24 | Repotrectinib, Crizotinib | NCT06140836A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | Phase 3 | 2026-03-13 | 2027-02-16 | +340 days |
| 2026-09-24 | zanubrutinib, Pirtobrutinib, Acalabrutinib, Ibrutinib | NCT04662255Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | Phase 3 | 2027-01 | 2027-11 | +304 days |
| 2026-09-24 | Zongertinib, pemetrexed, Pembrolizumab | NCT06151574Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | Phase 3 | 2026-09-02 | 2026-12-10 | +99 days |
| 2026-09-24 | Cabozantinib, Nivolumab | NCT07405164Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) | Phase 3 | 2034-01-14 | 2034-04-22 | +98 days |
| 2026-09-24 | Avelumab | NCT03815643Avelumab Program Rollover Study | Phase 3 | 2026-08-21 | 2026-11-24 | +95 days |
| 2026-09-24 | Finerenone | NCT07223502A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease | Phase 3 | 2026-07 | 2026-09-17 | +78 days |
| 2026-09-22 | Valsartan/amlodipine/chlorthalidone (AJU-C52) | NCT06416865Efficacy and Safety of AJU-C52 in Essential Hypertension Patients | Phase 3 | 2022-12-12 | 2024-12-23 | +742 days |
| 2026-09-22 | Dexamethasone, Lenalidomide, Carfilzomib | NCT04096066A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | Phase 3 | 2026-01-01 | 2027-09-01 | +608 days |
| 2026-09-22 | Tislelizumab, Nab-paclitaxel | NCT06258811Neoadjuvant Immunochemotherapy for LAOSCC | Phase 3 | 2026-12-30 | 2027-12-30 | +365 days |
| 2026-09-22 | Rimegepant (Nurtec ODT) | NCT07729462A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine | Phase 3 | 2028-09-12 | 2028-10-21 | +39 days |
| 2026-09-22 | Docetaxel | NCT03691454Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric Adenocarcinoma | Phase 2/3 | 2026-08-30 | 2026-09-30 | +31 days |
| 2026-09-22 | Sacubitril/valsartan | NCT03508739Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition | Phase 3 | 2026-06-01 | 2026-06-30 | +29 days |
| 2026-09-22 | tocilizumab | NCT07263776Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2 | Phase 3 | 2026-09-16 | 2026-09-18 | +2 days |
| 2026-09-19 | Docetaxel, Pembrolizumab | NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | Phase 3 | 2026-09-15 | 2026-11-20 | +66 days |
| 2026-09-19 | Methotrexate | NCT03371667To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids | Phase 3 | 2024-12 | 2025-01-24 | +54 days |
| 2026-09-18 | Serplulimab | NCT07177443Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma | Phase 3 | 2031-12-31 | 2035-12-31 | +1461 days |
| 2026-09-18 | Lenalidomide, Daratumumab | NCT04071457S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration | Phase 3 | 2029-07-01 | 2032-09 | +1158 days |
| 2026-09-18 | Bexicaserin | NCT06660394A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | Phase 3 | 2026-08-21 | 2026-12-31 | +132 days |
| 2026-09-17 | Bevacizumab | NCT05798819A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | Phase 3 | 2025-05-01 | 2029-12-31 | +1705 days |
| 2026-09-17 | Brexpiprazole (Rexulti) | NCT05325645Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia | Phase 3 | 2026-02 | 2027-09 | +577 days |
| 2026-09-16 | PF-06823859 | NCT05895786A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] | Phase 3 | 2027-07-28 | 2030-07-29 | +1097 days |
| 2026-09-16 | Blinatumomab | NCT07223190A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia | Phase 3 | 2030-05-10 | 2031-12-30 | +599 days |
| 2026-09-16 | Olverembatinib | NCT06423911Study of Olverembatinib (HQP1351) in Patients With CML-CP | Phase 3 | 2025-12 | 2027-06-30 | +576 days |
| 2026-09-16 | Capecitabine, Pembrolizumab | NCT06901531A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer | Phase 3 | 2027-03-31 | 2028-09-30 | +549 days |
| 2026-09-16 | tenofovir alafenamide (Vemlidy) | NCT05813964Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France. | Phase 3 | 2026-10 | 2027-12-31 | +456 days |
| 2026-09-16 | Semaglutide (Ozempic) | NCT05569772Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes | Phase 3 | 2029-06 | 2030-03 | +273 days |
| 2026-09-16 | Esketamine | NCT06051227Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial | Phase 3 | 2026-03 | 2026-08-06 | +158 days |
| 2026-09-15 | Giredestrant, Palbociclib, Fulvestrant, Ribociclib, Abemaciclib | NCT06065748A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Phase 3 | 2027-02-19 | 2028-04-20 | +426 days |
| 2026-09-15 | Pivekimab Sunirine, Azacitidine, Venetoclax | NCT07581002A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) | Phase 2/3 | 2032-05 | 2032-06 | +31 days |
| 2026-09-12 | deucravacitinib, apremilast | NCT04908189A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment | Phase 3 | 2024-02-06 | 2024-11-07 | +275 days |
| 2026-09-11 | Temozolomide | NCT07349693Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma | Phase 2/3 | 2028-12-01 | 2029-03-30 | +119 days |
| 2026-09-10 | Sodium zirconium cyclosilicate | NCT06578533Keeping RAASi Treatment With Optimal Potassium Control | Phase 3 | 2025-07-30 | 2027-07-30 | +730 days |
| 2026-09-10 | Azacitidine, Venetoclax | NCT06073730Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients | Phase 3 | 2024-11-01 | 2025-12-30 | +424 days |
| 2026-09-10 | Ziltivekimab | NCT06118281ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | Phase 3 | 2026-12-14 | 2027-01-29 | +46 days |
| 2026-09-10 | Umeclidinium, fluticasone furoate/umeclidinium/vilanterol, fluticasone furoate/vilanterol, Fluticasone Furoate | NCT05757102A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | Phase 3 | 2027-01-22 | 2027-01-26 | +4 days |
| 2026-09-09 | tofacitinib | NCT06172361Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica | Phase 3 | 2025-09-30 | 2026-05-30 | +242 days |
| 2026-09-09 | Semaglutide (Ozempic) | NCT07059377Semaglutide for Smoking Cessation in Patients With Diabetes | Phase 3 | 2026-07 | 2026-12 | +153 days |
| 2026-09-09 | bimekizumab | NCT04436640A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis | Phase 3 | 2026-08-07 | 2026-08-09 | +2 days |
| 2026-09-05 | Methotrexate, Cetuximab | NCT05751512A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN | Phase 3 | 2025-08 | 2027-12 | +852 days |
| 2026-09-05 | tilrekimig | NCT07765888A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema | Phase 3 | 2028-02-29 | 2028-03-10 | +10 days |
| 2026-09-04 | Ivosidenib, Enasidenib, Revumenib, Azacitidine, Venetoclax, Gilteritinib | NCT03013998Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | Phase 2/3 | 2028-12 | 2032-12 | +1461 days |
| 2026-09-04 | Pembrolizumab, Cetuximab | NCT07509099Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC | Phase 3 | 2030-09-30 | 2031-09-30 | +365 days |
| 2026-09-04 | Tremelimumab, Bevacizumab, Rilvegostomig, Atezolizumab | NCT06921785Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | 2029-03-16 | 2030-03-15 | +364 days |
| 2026-09-04 | Encorafenib, Binimetinib, Pembrolizumab | NCT04657991A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | Phase 3 | 2026-01-12 | 2026-10-30 | +291 days |
| 2026-09-04 | Gemcitabine, Vemurafenib, pemetrexed, Entrectinib, Divarasib, Cobimetinib, Alectinib, Bevacizumab, Atezolizumab | NCT03178552A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | Phase 2/3 | 2026-10-31 | 2027-06-30 | +242 days |
| 2026-09-04 | tezepelumab | NCT07363642Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab | Phase 3 | 2027-08-07 | 2028-02-07 | +184 days |
| 2026-09-04 | Pirfenidone (Esbriet) | NCT07284602Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | 2029-06 | 2029-11 | +153 days |
| 2026-09-04 | Palbociclib | NCT03820830Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | Phase 3 | 2026-07-27 | 2026-12 | +127 days |
| 2026-09-03 | Tenofovir alafenamide/emtricitabine | NCT05813964Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France. | Phase 3 | 2026-10 | 2027-12-31 | +456 days |
| 2026-09-03 | Docetaxel | NCT04540692Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer | Phase 3 | 2026-04 | 2027-04 | +365 days |
| 2026-09-03 | Venetoclax | NCT05939180VA vs DA for Newly Diagnosed Hig-risk AML | Phase 2/3 | 2025-10-01 | 2026-06-13 | +255 days |
| 2026-09-03 | Docetaxel, Gemcitabine | NCT07464145A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer | Phase 3 | 2029-09 | 2029-12 | +91 days |
| 2026-09-02 | Exemestane, Letrozole, Anastrozole, Tamoxifen (Soltamox) | NCT05645536Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | Phase 3 | 2028-06 | 2030-03 | +638 days |
| 2026-09-02 | Sitagliptin | NCT05972928Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients | Phase 2/3 | 2023-10-30 | 2025-04-30 | +548 days |
| 2026-09-02 | Hydroxychloroquine | NCT05287321The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia | Phase 3 | 2025-12-31 | 2026-12-31 | +365 days |
| 2026-09-02 | Capecitabine, Zanidatamab, Tislelizumab | NCT05152147A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | Phase 3 | 2026-07-31 | 2026-09-30 | +61 days |
| 2026-09-02 | Descartes-08 | NCT06799247Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | Phase 3 | 2026-11-30 | 2026-12-30 | +30 days |
| 2026-09-02 | SSGJ-611 | NCT06554847Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis | Phase 3 | 2025-10-12 | 2025-10-20 | +8 days |
| 2026-09-01 | SHR-1819 | NCT06468956Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis | Phase 3 | 2026-03-31 | 2026-12-31 | +275 days |
| 2026-08-29 | pemetrexed, Pembrolizumab, Nab-paclitaxel | NCT06096844Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Phase 3 | 2035-01-31 | 2039-04-01 | +1521 days |
| 2026-08-29 | ivarmacitinib | NCT04957550To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis | Phase 3 | 2024-11-13 | 2026-12-13 | +760 days |
| 2026-08-29 | Docetaxel, Gemcitabine, Sacituzumab Govitecan, Pembrolizumab | NCT06524544A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer | Phase 3 | 2028-12-31 | 2030-12-31 | +730 days |
| 2026-08-29 | Camrelizumab | NCT07235319PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC | Phase 3 | 2031-11-20 | 2032-04-16 | +148 days |
| 2026-08-29 | Pelacarsen | NCT04023552Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD | Phase 3 | 2026-06-30 | 2026-07-16 | +16 days |
| 2026-08-29 | apremilast | NCT06088199A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis | Phase 3 | 2026-08-06 | 2026-08-12 | +6 days |
| 2026-08-28 | Brexpiprazole (Rexulti) | NCT04569448Brexpiprazole Treatment for Bipolar I Depression | Phase 3 | 2025-02 | 2030-09 | +2038 days |
| 2026-08-28 | Docetaxel | NCT03691454Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric Adenocarcinoma | Phase 2/3 | 2022-06-30 | 2026-08-30 | +1522 days |
| 2026-08-28 | vedolizumab | NCT06337695Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer | Phase 2/3 | 2026-11-01 | 2030-12-01 | +1491 days |
| 2026-08-28 | Capecitabine, Gemcitabine | NCT05314998Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature | Phase 3 | 2031-01-01 | 2033-04-01 | +821 days |
| 2026-08-28 | insulin glargine | NCT05573477Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes | Phase 3 | 2024-01 | 2025-08-31 | +608 days |
| 2026-08-28 | MB12, pemetrexed, Pembrolizumab | NCT06687369A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | Phase 3 | 2026-06 | 2026-08-31 | +91 days |
| 2026-08-28 | Staccato Alprazolam | NCT05077904A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures | Phase 3 | 2026-08-31 | 2026-09-30 | +30 days |
| 2026-08-27 | Sotagliflozin (Inpefa) | NCT06481891A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Phase 3 | 2026-07 | 2027-01 | +184 days |
| 2026-08-27 | Ocrelizumab | NCT06846281Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Phase 3 | 2029-07-24 | 2029-07-25 | +1 day |
| 2026-08-26 | Bevacizumab, Atezolizumab | NCT04770896A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab | Phase 3 | 2026-06-30 | 2026-10-14 | +106 days |
| 2026-08-26 | Gemcitabine | NCT03533582Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | Phase 3 | 2026-12-31 | 2027-03-31 | +90 days |
| 2026-08-25 | Capecitabine, Docetaxel | NCT03801876Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | Phase 3 | 2026-12-21 | 2031-11-07 | +1782 days |
| 2026-08-25 | Gemcitabine, Nab-paclitaxel | NCT03257033Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Phase 3 | 2026-06 | 2027-06 | +365 days |
| 2026-08-25 | Esomeprazole | NCT07326904Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease | Phase 3 | 2024-10-10 | 2024-11-12 | +33 days |
Showing the newest 300 of 323 moves. Each drug page lists every registry date for its own studies.
Source: ClinicalTrials.gov, each study's record. A month-only date (YYYY-MM) is read as the first of the month, and a date that only gained or lost its day is not counted as a move. Every move we have recorded, not only the last 180 days, is a free CSV on the open data page.